TCH346

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Amyotrophic Lateral Sclerosis

Phase 2

A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis

CompletedNCT00036413

Novartis PharmaceuticalsAmyotrophic Lateral Sclerosis

Start: 2002-01-31End: 2002-10-31Updated: 2011-11-24

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT00072709

Novartis PharmaceuticalsAmyotrophic Lateral Sclerosis

Start: 2003-09-30End: 2004-12-31Updated: 2011-11-24

A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)

CompletedNCT00230074

NovartisAmyotrophic Lateral Sclerosis

Start: 2004-11-30End: 2005-02-28Updated: 2011-11-23